Argenta Discovery and TTP LabTech have announced a collaborative agreement to expand Argenta's biology and eAdmet capabilities
Argenta Discovery and TTP LabTech have announced a collaborative agreement to expand Argenta's biology and eAdmet capabilities through the incorporation of TTP LabTech's Acumen Explorer screening platform.
Argenta and TTP LabTech will also work together to develop novel screening assays within the drug discovery process.
The Acumen Explorer is a laser scanning fluorescence microplate cytometer that enables the development and execution of powerful cell-based high content screens.
The implementation of TTP LabTech's Acumen Explorer will expand Argenta's already comprehensive drug discovery offering and strengthen its position as a high quality provider of research services to the pharmaceutical industry.
In addition, Argenta and TTP LabTech have agreed a collaboration to develop novel assays to accelerate the drug discovery process, as an offering to the pharmaceutical industry to support Argenta's internal research programmes.
This collaboration will take advantage of TTP LabTech's proven track record in developing cutting edge assay technology and Argenta's expertise in drug screening and eAdmet.
"Argenta is committed to staying at the forefront of drug discovery and the implementation of industry leading technologies are key to achieving this goal.
With the incorporation of the Explorer technology, Argenta has further strengthened its biology services capability and has taken a major step towards becoming a leader in high-content screening" said Peter Lockey, Argenta's director of biology.
"TTP LabTech is widely recognised as a high quality provider of screening technology and Argenta is delighted to be working with them".
"Combining the Acumen Explorer microplate cytometer with Argenta's assay development and screening expertise will enable extensive assessment of both cell and biological processes central to drug discovery." added Wayne Bowen, chief scientific officer of TTP LabTech.
